Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
MENOSTAR |
| Manufacturer |
|
Bayer Corp, Pharmaceutical Div. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estradiol 0.014mg/day; transdermal patch. |
| Indications |
|
Postmenopausal osteoporosis prevention. |
| Children |
|
Not applicable. |
| Adults |
|
Apply to clean, dry area of lower abdomen (avoid breasts, waistline). One patch once weekly. Rotate application sites. |
| Contraindications |
|
Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Breast or estrogen-dependent carcinoma. Hepatic dysfunction. Pregnancy (Cat.X). |
| Precautions |
|
Reevaluate periodically. Hypercoagulability. Endometriosis. Severe hypocalcemia. Bone disease associated with hypercalcemia. Do initial complete physical exam and repeat annually (include BP, mammogram, Pap smear). Discontinue if jaundice or hypercalcemia occurs, and during immobilization or at least 2 weeks before surgery associated with increased risk of thromboembolism. Nursing mothers. |
| Interactions |
|
Plasma levels reduced by CYP3A4 inducers. Potentiated by CYP3A4 inhibitors. |
| Adverse Reactions |
|
See literature. Increased risk of endometrial cancer or hyperplasia, thromboembolic disorders, gallbladder disease. Local irritation, joint pain, leukorrhea, fluid retention, mastodynia, metrorrhagia, headache, rash. |
| How Supplied |
|
Patches—4 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
